Femoral Nerve Block Compared to Exparel in Total Knee Replacement



Status:Active, not recruiting
Conditions:Arthritis, Chronic Pain, Osteoarthritis (OA)
Therapuetic Areas:Musculoskeletal, Rheumatology
Healthy:No
Age Range:18 - 73
Updated:4/21/2016
Start Date:January 2014
End Date:February 2017

Use our guide to learn which trials are right for you!

A Prospective Randomized Trial Comparing Femoral Nerve Black to Intraoperative Local Anesthetic Injection of Liposomal Bupivacaine (Exparel) in Total Knee Replacement

The main objective of the study is to determine if intrarticular injection with liposomal
bupivicaine (Exparel) provides better postoperative pain relief and functional outcome
following total knee replacement (TKR) than the current standard New England Baptist
Hospital regimen of femoral nerve block combined with intraarticular injection of a standard
bupivicaine solution.

A prospective, single blind study comparing femoral nerve blockade and intraarticular
posterior capsular injection to interarticular injection of bupivicaine and liposomal
bupivicaine (Exparel) alone.

Inclusion Criteria:

• Patients between the ages of 18 - 73 who are undergoing primary, unilateral, Total Knee
Replacement at the New England Baptist Hospital in Boston, Massachusetts are eligible to
participate.

Exclusion Criteria:

- Patients with Revision or Complex Total Knee Replacements and are under the age of
18, or over the age of 73 will be excluded.

- Patients with an ASA 4 level will be excluded.

- Patients with a Body Mass Index of less than 20, and over 40, will be excluded.

- Patients taking preoperative narcotics, patients with extreme sensitivity or allergy
to narcotics or local anesthetics, and patients using opioid medications for at least
3 months leading up to surgery, will also be excluded.
We found this trial at
1
site
Boston, Massachusetts 02120
?
mi
from
Boston, MA
Click here to add this to my saved trials